Showing results (11-20 of 172) with videos related to
Sort By:
Pageof 18
Current Hematologic Malignancy Reports|April 29, 2010
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspectiveMartha Wadleigh, D Gary GillilandCurrent Opinion in Hematology|November 30, 2006
JAK-2 mutations and their relevance to myeloproliferative diseaseRoss L Levine, D Gary GillilandCurrent Opinion in Genetics & Development|January 9, 2007
Jak2: normal function and role in hematopoietic disordersJames N Ihle, D Gary GillilandBlood|August 15, 2002
The roles of FLT3 in hematopoiesis and leukemiaD Gary Gilliland, James D GriffinBest Practice & Research. Clinical Haematology|March 18, 2008
Can FLT3 inhibitors overcome resistance in AML?Winnie F Tam, D Gary GillilandCancer Cell|July 18, 2006
Cell-autonomous and -nonautonomous contributions of STAT1 in murine models of tumorigenesisJennifer L Rocnik, D Gary GillilandBiology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 16, 2002
Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantationD Gary Gilliland, John G GribbenCell Cycle (Georgetown, Tex.)|March 17, 2004
Oncogenic K-ras in mouse models of myeloproliferative disease and acute myeloid leukemiaIris T Chan, D Gary GillilandNature Reviews. Clinical Oncology|February 29, 2012
Drug development and clinical trials--the path to an approved cancer drugEric H Rubin, D Gary GillilandPageof 18